dsm-firmenich presenteert de eerste wereldwijde resultaten waarin hun nieuwe CBD-formulering CBtru® wordt vergeleken met Epidiolex.
Deze Fase I klinische studie toont aan dat CBtru® een gelijkwaardige of betere biologische beschikbaarheid biedt dan de huidige gouden standaard, met minder variabiliteit tussen proefpersonen en een verminderde voedselafhankelijkheid. Deze doorbraak in de vaste formulering zou de toediening van CBD-medicijnen kunnen veranderen met handigere doseringsopties en een verbeterde ervaring voor de patiënt.
Spreker:
Deze sessie duurt 20 minuten.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Discover how pharmaceutical quality management is advancing through proactive strategies that reduce risk, improve visibility, and support compliance.
Discover how dsm-firmenich and Bayer reduced vitamin C’s carbon footprint by 49% through renewable energy, process innovation, and sustainable pharma collaboration.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.